[go: up one dir, main page]

CN1535681A - 降低哺乳动物血糖水平的二肽基肽酶iv效应物的用途 - Google Patents

降低哺乳动物血糖水平的二肽基肽酶iv效应物的用途 Download PDF

Info

Publication number
CN1535681A
CN1535681A CNA2003101131191A CN200310113119A CN1535681A CN 1535681 A CN1535681 A CN 1535681A CN A2003101131191 A CNA2003101131191 A CN A2003101131191A CN 200310113119 A CN200310113119 A CN 200310113119A CN 1535681 A CN1535681 A CN 1535681A
Authority
CN
China
Prior art keywords
dipeptidyl peptidase
effectors
glp
glucose
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2003101131191A
Other languages
English (en)
Other versions
CN1269528C (zh
Inventor
H-U����ķ˼
H－U·德姆思
F·罗施
J·施密德
R·P·帕里
S��������ʲ
C·H·S·麦克恩多什
���˹���Ѷ���
R·A·佩德逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
BIOLOGICAL MEDICINE AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7792391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1535681(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BIOLOGICAL MEDICINE AG filed Critical BIOLOGICAL MEDICINE AG
Publication of CN1535681A publication Critical patent/CN1535681A/zh
Application granted granted Critical
Publication of CN1269528C publication Critical patent/CN1269528C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

本发明涉及一种方法的用途，其中，通过施用效应物来降低哺乳动物血液中二肽基肽酶(DP IV)－以及DP IV类似物－酶活性，将导致内源(或者外源施用)的促胰岛素肽(肠促胰岛素)、抑胃多肽1－42(GIP1－42)以及高血糖素样肽酰胺－17－36(GLP－17－36)(或类似地GLP－17－37或这些肽的类似物)降解至一个较低的含量。由此这些肽激素或其类似物的浓度降低(导致由DP IV和DP IV类似物－酶降解)将被减少或者延迟。由于DP IV效应物的作用，由内源性或外源性施用可得的肠促胰岛素或其类似物的提高了的稳定性改变了内源胰岛素的能力并由此刺激在被处理有机体中碳水物质的代谢。因此被处理有机体血清中血糖水平降低至低于表征高血糖的葡萄糖浓度之下。

Description

降低哺乳动物血糖水平的二肽基肽酶IV效应物的用途
本发明是申请日为1997年4月24日、申请号为97194017.7、发明名称为降低哺乳动物血糖水平的二肽基肽酶IV效应物的用途的中国专利申请的分案申请。
技术领域
本发明涉及一种降低血糖浓度的简单的方法，该方法借助对与二肽基肽酶IV的酶促活性有类似或相同的活性的酶进行抑制的效应物(底物、假底物、抑制剂、结合蛋白、抗体和其类似物)来降低血糖浓度。
背景技术
除了与非特异蛋白酶解的蛋白酶有关以外，导致蛋白质特异性降解的蛋白酶为大家所熟知，这与内源性肽的功能调节(活化、失活或调节)有关[KIRSCHKE，H.，LANGNER，J.RIEMANN，S.，WIEDERANDERS，B.，ANSORGE，S.和BOHLEY，P.，溶酶体半胱氨酸蛋白酶.ExcerptaMedica(Ciba基础专题研讨75)，15(1980)；KRUSSLICH，H.-G.和WIMMER，E.，病毒蛋白酶.生物化学年度综述57，701(1987)]。
在免疫系统研究和神经肽研究中已经发现了所谓的转化酶、信号肽酶或脑腓肽酶[GOMEZ，S.，GLUSCHANKOF，P.，LEPAGE，A.，MARRAKCHI，N.和COHEN，P.美国国家科学院院报85，5468(1988)；ANSORGE，S.和SCHN，E.，组织化学82，41(1987)]。
由于氨基酸脯氨酸在许多肽激素中非常丰富且由此决定这些肽的一定结构性质，因此将脯氨酸特异的肽酶当作一种对信号肽酶的有类似功能的酶讨论[YARON，A.，在生物活性肽的蛋白水解调节中脯氨酸的作用。生物高聚物(1987)26，215；WALTER，R.，SIMMONS，W.H.和YOSHIMOTO，T.，脯氨酸特异性内肽酶和外肽酶，分子细胞生物化学30，111(1980)；VANHOOF，G.，GOOSSENS，F.，DE MEESTER，I.，HENDRIKS，D.和
Figure A20031011311900041
S.，脯氨酸基元和它们的生物加工。FASEB期刊9，736(1995)]。由于它的例外结构，在这种肽中脯氨酸决定着它们的构象和稳定性，以阻止由非特异蛋白酶导致的降解。[KESSLER，H.，构象和生物活性。应用化学94，509(1982)]。相对地，对脯氨酸包含的序列(包括HIV-蛋白酶，cyclophylin等等)具有高度特异性能力的酶是药物化学的具有吸引力的靶。尤其是，将后脯氨酸切割的肽酶(如脯氨酰内肽酶(PEP)和二肽基肽酶IV(DP IV)的活性)与天然肽底物的生物活性的调节和它们的由这些酶的选择性切割联系起来。有人指出PEP与记忆和学习有关，并且DP IV在免疫应答期间参与信号转导[ISHIURA，S.，TSUKAHARA，T.TABIRA，T.SHIMLZU，T.，ARAHATA K和SUGITA，H.，FEBS-通讯(1990)260，131；HEGEN，M.，NIEDOBITEK，G.，KLEIN，C.E.，STEIN，H.和FLETSCHER，B.，免疫学杂志144，2908(1990)]。
除它们有突出的相似于高脯氨酸的特异性之外，在这些酶的底物的典型识别区中有能够选择性地识别氨基酸丙氨酸的高选择性。据此，人们认为含丙氨酸的肽在结构上可采用与结构类似的含脯氨酸的肽类似的构象。前不久，含脯氨酸的肽链的这类性质已通过基因点突变(脯氨酸交换丙氨酸)[DODGE R.W.和SCHERAGA，H.A.，牛胰核糖核酸酶A的脯氨酸-向-丙氨酸突变体的折叠和解折叠动力学，生物化学35(5)1548(1996)]。
在由生物活性肽的N端释放高活性二肽的地方，当脯氨酸或丙氨酸是序列中N-末端氨基酸的相邻残基时，血液循环中存在的DPIV-或DP IV类似物-的活性(例如胞质DP II具有与DP IV的几乎同样的底物特异性)是高度特异性的。因此，这种酶参与了体内多肽的活性调节[VANHOOF，G.，COOSSENS，F.，DE MEESTER，I.，HENDRIKS，D.和 S.，脯氨酸基元和它们的生物加工，FASEB期刊9，736(1995)]。
糖依赖性胰岛素释放肽：抑胃多肽1-42(GIP1-42)和胰高血糖素样肽酰胺-1 7-36(GLP-17-36)一它们是刺激从胰腺(肠促胰岛素)分泌葡萄糖诱导的胰岛素的激素-是DP IV的底物，因为它们分别在体外和体内从这些肽的N-末端序列释放二肽酪氨酰-丙氨酸和组氨酰-丙氨酸[MENTLEIN，R.，GALLWITZ，B.，和SCHMLDT，W.E.：二肽基肽酶IV水解抑胃多肽、胰高血糖素样肽-1(7-36)酰胺、肽组氨酸甲硫氨酸，并且在人血清中对它们的降解负责，欧洲生物化学杂志214，829(1993)]。
在哺乳动物中，在实验室条件和病理状态下，在体内降低由DPIV-或DP IV类似物-酶活性对这种底物的切割可能用于有效抑制不合乎需要的酶促活性[DEMUTH，H.-U.，在丝氨酸和半胱氨酸蛋白酶的不可逆抑制方面的最新进展，酶抑制杂志，3，249-278(1990)；DEMUTH，H.-U.和HEINS，J.，在二肽基肽酶IV(CD 26)的代谢和免疫应答中二肽基肽酶IV的催化机理(B.Fleischer，编著)R.G.Landes，生物药物出版社，Georgetown，1-35(1995)]。例如，II型真性糖尿病(以及老年性糖尿病)是基于胰岛素分泌受阻或受体功能的紊乱，除了其它因素外，这是酶解决定的分泌物浓度异常的原因[BROWN，J.C.，DAHL，M.，KWAWK，S.，MCINTOSH，C.H.S.，OTTE，S.C和PEDERSON，R.A.肽2，241(1981)；SCHMLDT，W.E.SIEGEL，E.G.，GALLWITZ，B.KUMMEL，H.，EBERT，R和CREUTZFELDT，W.，从抑胃多肽衍生的片段的促胰岛素活性的鉴定，糖尿病生理学29，591A(1986)；ADELHORST，K.，HEDEGAARD，B.B.，KNUDSEN，L.B.和KIRK，O.，胰高血糖素样肽的结构活性研究，生物化学杂志296，6275(1994)]。
按照现有技术，通过利用不同的施用形式给患者施用胰岛素(例如从牛或猪胰分离的或者由基因工程获得的材料)来治疗高血糖和与此有关的病因和后遗症。至今已知的以及较现代的治疗方法表现出高耗费以及对患者身体状况的强烈损害。经典的方法(每日进行静脉内胰岛素注射，从三十年代就已经利用)处理急性症状，但是在应用较长时间后将导致血管变形(动脉硬化)和神经性损伤[LACY，P.，脉间区细胞移植的状态，糖尿病护理16(3)76(1993)]。
更现代的方法，如皮下贮存植入物的安装(成功地计量胰岛素释放，取消每日注射)以及在功能紊乱的胰腺或其它器官和组织中植入朗氏细胞完整脉间区(移植)正在试验中。然而，这样的移植昂贵。另外，它们表示出高风险的外科手术排斥反应，并且在采用移植方法时要求进行免疫抑制或者避开免疫应答。[LACY，P.，用移植细胞治疗糖尿病，美国科学273(1)40-46(1995)]。
与上述疗法相比，尽可能地口服高效的低分子量酶抑制剂是在处理病理现象时的、一种对于例如侵害性的外科手术方法的非常有效的替代选择方案。这类酶抑制剂找到了在治疗中的用途，以用作抗高血压药物、免疫抑制药物以及抗艾滋病毒剂。通过对分子的稳定性、转录和裂变性质进行化学设计，可以改进它们的功效，并且使它们在有机体之间适应个体的区别。[SANDLER，M.和SMLTH，H.J.，编著，作为药物的酶抑制剂的设计，牛津大学出版社，牛津大学(1989)；MUNROE，J.E.，SHEPHEAD，T.A.，JUNGHEIM，L.N.，HORNBACK，W.J.，HATCH，S.D.，MUESTNG，M.A.，WISKERCHEN，M.A.，SU，K.S.，CAMPANALE，K.M.，BAXTER，A.J.和COLACINO，J.M.，包含非编码的D-氨基酸的有效的口服的HIV-1蛋白酶抑制剂，生物药物化学通讯5(23)2987(1995)]。
发明内容
本发明的目的是提供一种降低血糖水平的简单的并且新的方法，其中通过给哺乳动物服用酶的效应物，使所说酶的效应物诱导DP IV-酶的或者DP IV类似物-酶的活性降低，这将导致内源的(或外源施用的)促胰岛素肽抑胃多肽1-42(GIP1-42)和胰高血糖素样肽酰胺-17-36(GLP-17-36或这些肽的类似物)的降解减少。因此，将阻止或者延迟这些肽激素或它们类似物在浓度上的减少。
本发明基于这样一个惊人的发现：在血液循环中，二肽基肽酶DP IV酶的或者DP IV类似物-酶的活性降低将导致改进的葡萄糖耐受性。我们观察到：
1.降低二肽基肽酶DP IV-或DP IV类似物-酶活性导致葡萄糖刺激的内源释放的或外源施用的肠降血糖素(或其类似物)稳定性相对地提高，因此通过服用DP IV-或DP IV类似物-蛋白质的活性抑制效应物，可以控制肠降血糖素在血液中的降解。
2.肠降血糖素(或其类似物)的提高了的生物降解稳定性导致胰岛素作用效果改进。
3.由降低二肽基肽酶DP IV-或DP IV类似物-酶活性引起的肠降血糖素稳定性的升高将导致葡萄糖诱导的胰岛素作用随后改变，且借此导致一种可借助DP IV效应物控制性调节的血糖水平。
因此，本发明涉及二肽基肽酶DP IV-或者DP IV类似物-酶活性的活性抑制效应物的用途，用于将血糖水平降低至哺乳动物血中表征高血糖水平的葡萄糖浓度之下。本发明尤其涉及DP IV-或DP IV类似物-酶活性效应物在预防或者减轻哺乳动物代谢中的病理变态如葡糖尿、超脂血症、代谢性酸中毒和糖尿病中的应用。在一个更优选的实施方案中，本发明涉及降低哺乳动物血中血糖浓度至表征高血糖水平的葡萄糖浓度之下的方法。其特征在于，给哺乳动物服用治疗有效量的二肽基肽酶DP IV-或DP IV类似物-酶活性的效应物。
在第二个优选的实施方案中，本发明涉及二肽基肽酶DP IV-或DP IV类似物-酶活性的活性抑制效应物，它用于降低哺乳动物血中血糖浓度至表征提高血糖葡萄糖浓度之下的方法中。
按照本发明，施用的DP IV-和DP IV类似物-酶的活性抑制效应物作为酶抑制剂、底物、假底物、DP IV-表达物的抑制剂、结合蛋白或所说的酶蛋白的抗体或者作为这些不同化合物的组合体用于可用作药物的配方复合体中，这些效应物减少在哺乳动物中DP IV-和DP IV类似物-蛋白质的浓度。按照本发明的效应物例如是DPIV-抑制物如二肽衍生物或如丙氨酰-吡咯烷酰胺(pyrolidid)、异亮氨酰-四氢噻唑之类的二肽模仿物，以及假底物N-结氨酰-脯氨酰，O-苯甲酰羟胺。这些化合物从文献中是已知的[DEMUTH，H.-U.，在丝氨酸以及半胱氨酸蛋白酶的不可逆抑制方面的最新进展，酶抑制杂志3，249(1990)]，或者可以按照文献所描述的方法进行合成。
按照本发明的方法是一种降低哺乳动物血液中升高了的血糖浓度的新方法。本方法简单、制药学上有用，并且适用于制备治疗尤其是人类疾病的药物，这些疾病是基于超过正常血糖水平引起的。
将效应物以药物制剂形式进行施用，该制剂包含有效成分和常规的、从现有技术已知的载体材料。例如将它们以肠胃外(静脉内，以生理盐溶液)或经肠道(口服，与通常的载体材料形成配方)施用。
取决于效应物的内源稳定性和生物利用率，要进行一次或多次给药，以达到所预期的血糖浓度正常化。例如在用氨基酰基-四氢噻唑的情况下，剂量可以在1.0-10.0mg效应物物质/kg的范围内变化。
附图说明
附图1显示了对GIP1-42(b)和GLP-7-36用DP IV催化的水解和异亮氨酰-四氢噻唑对它们的抑制进行MALDI-TOF-分析
附图2显示了体内存在或不存在DP IV抑制剂异亮氨酰-四氢噻唑时GLP-1代谢物在血清中含量的HPLC-分析
附图3显示了DP IV-抑制剂异亮氨酰-四氢噻唑对十二指肠内葡萄糖刺激的鼠的不同血参数的影响
具体实施方式
实施例1.在体内肠促胰岛素GIP-1-42和GLP-17-36的DP IV-催化水解的抑制作用
体内利用纯化的酶或现场利用混合人血清可以证明，由DP IV-和DP IV类似物-酶促活性引起的肠促胰岛素的水解、或借助抑制剂可对它进行抑制(图1)。
按照本发明，在体内通过温育30μM GIP1-42或30μM GLP-17-36和20μM异亮氨酰-四氢噻唑(1a)，在24小时内实现对两种肽激素的酶催化水解的完全抑制(1b和1c，各见上面谱图)，上述温育物在pH7.6和30℃下是在20％混合血清中的可逆DP IV-抑制物。在pH7.6和30℃下，将合成的抑胃多肽GIP1-42(5μM)和合成的GLP-17-36(15μM)用在0.1mM TRICINE缓冲液中的人血清(20％)温育24小时。在不同时间间隔之后，取出温育分析样品(对于GIP1-422.5pmol，对于GLP-17-367.5pmol)。将样品利用2′，6′-二羟乙酰苯酮作为基质进行共结晶，并且通过MALDI-TOF-质谱分析法进行分析。谱图(图1)显示，每样品中有250个单个激光激发的积累。
(1b)在范围m/z 4980.1±5.3中的信号对应于GIP1-42(M4975.6)，并且在范围m/z 4745.2±5.5中的信号对应于DP IV-水解产物GLP-13-42(M4740.4)。
(1c)信号m/z 3325.0±1.2对应于GLP-17-36(M3297.7)，并且信号m/z 3116.7±1.3对应于DP IV-水解产物GLP-19-36(M3089.6)。
在不包含任何抑制剂的参照分析试样中，在这种时间内肠促胰岛素几乎完全降解(图1b和1c，各见下面的谱图)。
实施例2.通过体内的DP IV-抑制剂异亮氨酰-四氢噻唑抑制GLP-17-36的降解
与一个对照样相对照，跟踪分析鼠血清中天然肠促胰岛素(此处为GLP-17-6)的代谢对DP IV-抑制剂异亮氨酰-四氢噻唑(静脉内注射包含1.5μM抑制剂的0.9％食盐溶液)的依赖关系。在用抑制剂处理过的供试动物(N＝5)中，以浓度为每千克供试鼠用0.1mg抑制剂异亮氨酰-四氢噻唑试验时，促胰岛素肽激素GLP-17-36在实验期间没有观察到发生了降解(图2)。
在存在和不存在DP IV-抑制剂时，为了检测肠促胰岛素的代谢物，在开始静脉内施用抑制剂或食盐水20分钟后，将供验和参照动物进一步静脉内注射50-100pM125I-GLP-17-36(大约1μCi/pM比活)。温育2-5分钟后收集血样，并且利用20％乙腈提取原生质。随后，在RP-HPLC上分离所说的肽提取物并且在γ-计数器上分析样品的放射活性。将实测数据表达为相对于最大值的每分钟计数次数(cpm)。
实施例3.在体内静脉内施用DP IV-抑制剂异亮氨酰-四氢噻唑后胰岛素作用的调节和血糖水平的下降。
在通过对十二指肠内(i.d.)注射葡萄糖刺激的鼠身上，可通过体内施用不同的DP IV-效应物例如每千克鼠重0.1mg异亮氨酰-四氢噻唑，观测到归因于抑制剂效果的、时间上延迟发生作用的葡萄糖水平下降。这种效果取决于剂量，且在停止注射每千克鼠重0.05mg/分钟DP IV-抑制剂异亮氨酰-四氢噻唑后，效果是可逆的。与十二指肠内葡萄糖刺激的供试动物相反，将抑制剂处理的和对照用的动物作静脉内施用相同量的葡萄糖后，没有观察到可比的作用。图3显示了这些抑制剂依赖性的原生质参数的改变：A-DP IV-活性、B-原生质-胰岛素水平、C-血糖水平。
试验动物(N＝5，雄性Wistar-鼠，200-225g)最初获得含于0.9％食盐溶液中的1.5μM异亮氨酰-四氢噻唑(▲)或不含抑制剂的相同体积0.9％食盐溶液(■)(对照组，n＝5)。试验组在30分钟实验时间内另外获得0.75μM/分钟的抑制剂注射(*)。将对照组在相同的时间间隔期间注入0.9％的无抑制剂的食盐溶液。在开始时间T＝0时，将所有动物十二指肠内施用葡萄糖剂量为1g/kg 40％的葡萄糖溶液(w/v)。
在10分钟时间间隔内收集所有试验动物的血样。当在原生质中的DP IV-活性和胰岛素浓度被分析时，利用全血(Lifescan OneTouch II分析器)分析葡萄糖含量。
所采用的胰岛素测定法在10至160mU/ml的范围内是敏感的[PEDERSON，R.A.，BUCHAN，A.M.J.，ZAHEDI-ASH，S.，CHEN，C.B.和BROWN，J.C.Reg.Peptides.3，(1982)]。通过光谱分析法确定DP IV-活性[DEMUTH，H.-U.和HEINSI J.，二肽基肽酶IV(CD26)在代谢和免疫应答中二肽基肽酶IV的催化机理，(B.Fleischer，编)R.G.Landes，生物医学出版社，Georgetown，1-35(1995)]。所有数据以平均值加标准偏差给出。

Claims (4)

1.二肽基肽酶IV或二肽基肽酶IV样-酶活性的活性抑制效应物用于制备药物的用途，所述药物用于口服给药治疗基于表征高血糖的哺乳动物血清中的葡萄糖浓度的疾病。
2.按照权利要求1的用途，其特征在于，所述药物用于预防或者减轻下列哺乳动物代谢病理变态：葡糖尿，高脂血症，代谢性酸中毒和糖尿病。
3.按照权利要求1的用途，其特征在于，其中所述能够抑制二肽基肽酶IV或二肽基肽酶IV样-酶活性的效应物可采用所述酶的抑制剂、底物、假底物、二肽基肽酶-表达物抑制剂、这些酶蛋白的结合蛋白质或者抗体、或者所说效应物的组合物。
4.按照权利要求1的用途，其特征在于，所述效应物是异亮氨酰-四氢噻唑。
CNB2003101131191A 1996-04-25 1997-04-24 降低哺乳动物血糖水平的二肽基肽酶iv效应物的用途 Expired - Lifetime CN1269528C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19616486.9 1996-04-25
DE19616486.9A DE19616486C5 (de) 1996-04-25 1996-04-25 Verfahren zur Senkung des Blutglukosespiegels in Säugern

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN97194017A Division CN1132578C (zh) 1996-04-25 1997-04-24 降低哺乳动物血糖水平的二肽基肽酶iv效应物的用途

Publications (2)

Publication Number Publication Date
CN1535681A true CN1535681A (zh) 2004-10-13
CN1269528C CN1269528C (zh) 2006-08-16

Family

ID=7792391

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB2003101131191A Expired - Lifetime CN1269528C (zh) 1996-04-25 1997-04-24 降低哺乳动物血糖水平的二肽基肽酶iv效应物的用途
CN97194017A Expired - Lifetime CN1132578C (zh) 1996-04-25 1997-04-24 降低哺乳动物血糖水平的二肽基肽酶iv效应物的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN97194017A Expired - Lifetime CN1132578C (zh) 1996-04-25 1997-04-24 降低哺乳动物血糖水平的二肽基肽酶iv效应物的用途

Country Status (21)

Country Link
US (1) US6303661B1 (zh)
EP (3) EP0896538B1 (zh)
JP (3) JP2001510442A (zh)
KR (5) KR20050104428A (zh)
CN (2) CN1269528C (zh)
AT (1) ATE202705T1 (zh)
AU (1) AU721477C (zh)
CA (1) CA2252576C (zh)
DE (5) DE122010000020I1 (zh)
DK (2) DK0896538T3 (zh)
ES (2) ES2158562T3 (zh)
FR (1) FR14C0089I1 (zh)
GR (1) GR3036788T3 (zh)
LT (3) LTPA2014044I1 (zh)
LU (7) LU91334I2 (zh)
NL (2) NL300280I2 (zh)
NZ (1) NZ332707A (zh)
PT (2) PT896538E (zh)
RU (1) RU2189233C2 (zh)
SI (1) SI1084705T1 (zh)
WO (1) WO1997040832A1 (zh)

Families Citing this family (300)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
US20020006899A1 (en) * 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
CN1163594C (zh) 1997-09-29 2004-08-25 尖端医疗有限公司 体外造血细胞的刺激
JP4095772B2 (ja) 1997-11-18 2008-06-04 財団法人微生物化学研究会 新規生理活性物質スルフォスチン、その製造法及びその用途
AU2007202745B2 (en) * 1998-02-02 2010-11-18 1149336 Ontario, Inc. Method of regulating glucose metabolism, and reagents related thereto
CA2819705C (en) * 1998-02-02 2014-07-08 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
US6255772B1 (en) 1998-02-27 2001-07-03 Micron Technology, Inc. Large-area FED apparatus and method for making same
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828113A1 (de) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) * 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19834591A1 (de) * 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Verfahren zur Steigerung des Blutglukosespiegels in Säugern
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
US20030176357A1 (en) * 1998-10-06 2003-09-18 Pospisilik Andrew J. Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
WO2000058360A2 (en) 1999-03-29 2000-10-05 Uutech Limited Analogs of gastric inhibitory peptide and their use for treatment of diabetes
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
DE19926233C1 (de) 1999-06-10 2000-10-19 Probiodrug Ges Fuer Arzneim Verfahren zur Herstellung von Thiazolidin
DE19940130A1 (de) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
CA2390231A1 (en) * 1999-11-12 2001-05-17 Paul Jackson Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
GB9928330D0 (en) * 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
NZ531929A (en) * 1999-12-23 2006-01-27 Novartis Ag Use of nateglinide as a hypoglycemic agent for treating impaired glucose metabolism
US6380398B2 (en) 2000-01-04 2002-04-30 Novo Nordisk A/S Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
DK1741446T3 (da) * 2000-01-21 2008-06-02 Novartis Pharma Ag Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
JP2003520849A (ja) * 2000-01-24 2003-07-08 ノボ ノルディスク アクティーゼルスカブ 酵素ｄｐｐ−ｉｖの阻害剤であるｎ−置換２−シアノピロールおよび−ピロリン
AU2001233622A1 (en) * 2000-02-25 2001-09-03 Novo-Nordisk A/S Inhibition of beta cell degeneration
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
ES2525041T3 (es) 2000-03-31 2014-12-16 Royalty Pharma Collection Trust Método para la mejora de la señalización de islotes en diabetes mellitus y para su prevención
AR033390A1 (es) 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US7132104B1 (en) 2000-10-27 2006-11-07 Probiodrug Ag Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
EP1891948A1 (en) 2000-10-27 2008-02-27 Probiodrug AG Treatment of neurological and neuropsychological disorders
IL155157A0 (en) * 2000-10-27 2003-10-31 Probiodrug Ag Pharmaceutical compositions containing an attractin inhibitor
CZ306435B6 (cs) * 2000-12-14 2017-01-25 Ortho-Mcneil Pharmaceutical, Inc. Steroidní hormonální přípravek a způsob jeho přípravy
WO2002051836A1 (en) * 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
DE10100053A1 (de) * 2001-01-02 2002-08-22 Keyneurotek Ag I G Verwendung von Enzyminhibitoren der Dipeptidylpeptidase IV sowie der Aminopeptidase N und pharmazeutischen Zubereitungen daraus zur Prävention und/oder Therapie Ischämie-bedingter akuter und chronischer neurodegenerativer Prozesse und Erkrankungen
SI1757606T1 (sl) * 2001-02-24 2009-10-31 Boehringer Ingelheim Pharma Ksantinski derivati za uporabo kot zdravila kot tudi postopek za njihovo pripravo
JP2004525929A (ja) 2001-03-27 2004-08-26 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病の治療または予防用のジペプチジルペプチダーゼ阻害薬
US6890905B2 (en) 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
GB0109146D0 (en) * 2001-04-11 2001-05-30 Ferring Bv Treatment of type 2 diabetes
US20030060494A1 (en) * 2001-05-18 2003-03-27 Nobuyuki Yasuda Pharmaceutical use of N-carbamoylazole derivatives
FR2826003B1 (fr) * 2001-06-18 2003-08-15 Servier Lab Nouveaux derives cycliques d'alpha-amino-gamma-hydroxy- amides, leur procede de preparation et les compositions pharmaceutiques que les contiennent
WO2003000181A2 (en) 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
WO2003000180A2 (en) 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
RU2299066C2 (ru) * 2001-06-27 2007-05-20 Пробиодруг Аг Новые ингибиторы дипептидилпептидазы iv и их применение в качестве противораковых агентов
ATE374181T1 (de) 2001-06-27 2007-10-15 Smithkline Beecham Corp Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren
DE10150203A1 (de) 2001-10-12 2003-04-17 Probiodrug Ag Peptidylketone als Inhibitoren der DPIV
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US20040214762A1 (en) * 2001-08-16 2004-10-28 Hans-Ulrich Demuth Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
US7727964B2 (en) 2001-11-26 2010-06-01 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
EP1466610A4 (en) * 2001-11-26 2007-03-21 Daiichi Asubio Pharma Co Ltd MEDICAL COMPOSITIONS FOR RECEIVING VIA THE NOSE
WO2003045228A2 (en) * 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
ES2252656T3 (es) 2002-02-13 2006-05-16 F. Hoffmann-La Roche Ag Nuevos derivados de piridina y quinolina.
BR0307665A (pt) 2002-02-13 2005-01-04 Hoffmann La Roche Compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades associadas com dpp iv e utilização dos compostos
US7074798B2 (en) 2002-02-25 2006-07-11 Eisai Co., Ltd Xanthine derivative and DPPIV inhibitor
NZ534877A (en) 2002-02-28 2006-05-26 Prosidion Ltd Glutaminyl based DPIV inhibitors
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
DE10211555A1 (de) * 2002-03-15 2003-10-02 Imtm Inst Fuer Medizintechnolo Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention dermatologischer Erkrankungen mit sebozytärer Hyperproliferation und veränderten Differenzierungszuständen
JP2005526811A (ja) * 2002-03-25 2005-09-08 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病の治療または予防用β−アミノ複素環式ジペプチジルペプチダーゼ阻害剤
US20030232761A1 (en) * 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
ATE422884T1 (de) * 2002-06-03 2009-03-15 Novartis Pharma Gmbh Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie
US6710040B1 (en) * 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
ATE451369T1 (de) * 2002-07-15 2009-12-15 Merck & Co Inc Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US20040058876A1 (en) * 2002-09-18 2004-03-25 Torsten Hoffmann Secondary binding site of dipeptidyl peptidase IV (DP IV)
EP1543023B1 (en) * 2002-09-18 2010-03-17 Prosidion Limited Secondary binding site of dipeptidyl peptidase iv (dp iv)
US7262207B2 (en) 2002-09-19 2007-08-28 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20060094722A1 (en) * 2002-09-26 2006-05-04 Eisai Co., Ltd. Combination drug
AU2003275404A1 (en) * 2002-10-07 2004-05-04 Merck & Co., Inc. Antidiabetic beta-amino heterocyclic dipeptidyl peptidase inhibitors
AU2003298596B2 (en) * 2002-10-18 2008-12-18 Merck Sharp & Dohme Corp. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
BR0315796A (pt) 2002-11-07 2005-09-13 Merck & Co Inc Composto, composição farmacêutica, e, métodos para tratar diabetes, para tratar hiperglicemia, e para tratar obesidade em um mamìfero
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
CA2508487A1 (en) * 2002-12-04 2004-06-17 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
AU2003297219A1 (en) * 2002-12-20 2004-07-22 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
ES2295816T3 (es) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
JP4564952B2 (ja) 2003-01-17 2010-10-20 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての３−アミノ−４−フェニルブタン酸誘導体
PT1595866T (pt) 2003-01-31 2016-09-14 Sanwa Kagaku Kenkyusho Co Cianopirrolidinas úteis para o tratamento entre outras de síndrome metabólica
EP1592689A4 (en) * 2003-01-31 2008-12-24 Merck & Co Inc 3-AMINO-4-PHENYLBUTANEAN DERIVATIVES AS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
US20040242566A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7371871B2 (en) 2003-05-05 2008-05-13 Probiodrug Ag Inhibitors of glutaminyl cyclase
KR20110059664A (ko) 2003-05-05 2011-06-02 프로비오드룩 아게 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
AU2004237408C9 (en) 2003-05-05 2010-04-15 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases
EP1625122A1 (en) 2003-05-14 2006-02-15 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
DE602004023932D1 (de) * 2003-05-14 2009-12-17 Merck & Co Inc 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
AU2004247068A1 (en) * 2003-06-06 2004-12-23 Merck & Co., Inc. Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP4579239B2 (ja) * 2003-06-17 2010-11-10 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療または予防するためのジペプチジルペプチダーゼ阻害剤としてのシクロヘキシルグリシン誘導体
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
BRPI0411509A (pt) 2003-06-20 2006-07-25 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização
MXPA05013904A (es) 2003-06-20 2006-02-24 Hoffmann La Roche Derivados de pirido[2,1-a] isoquinolinas como inhibidores de dipeptidil-peptidasa iv(dpp-iv).
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
US20060241019A1 (en) * 2003-07-25 2006-10-26 Bridon Dominique P Long lasting insulin derivatives and methods thereof
US7259160B2 (en) * 2003-07-31 2007-08-21 Merck & Co., Inc. Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2535619A1 (en) 2003-08-13 2005-02-24 Takeda Pharmaceutical Company Limited 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
CN1867324A (zh) * 2003-10-15 2006-11-22 前体生物药物股份公司 谷氨酰胺酰基环化酶效应物和谷氨酸环化酶效应物的应用
CA2543181A1 (en) * 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
US20100099721A1 (en) * 2003-11-03 2010-04-22 Probiodrug Ag Novel compounds for the treatment of neurological disorders
US20050171112A1 (en) * 2003-11-03 2005-08-04 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
WO2005049027A2 (en) 2003-11-03 2005-06-02 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
CA2541212A1 (en) * 2003-11-04 2005-05-19 Wallace T. Ashton Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
WO2005047297A1 (en) 2003-11-12 2005-05-26 Phenomix Corporation Heterocyclic boronic acid compounds
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
KR20130105741A (ko) 2003-11-17 2013-09-25 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
DE10355304A1 (de) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
BR122018014389B1 (pt) 2004-01-20 2023-04-25 Novartis Ag Processo para preparar comprimido farmacêutico por compressão direta
US7230002B2 (en) 2004-02-03 2007-06-12 Glenmark Pharmaceuticals Ltd. Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof
BRPI0507485A (pt) 2004-02-05 2007-07-10 Probiodrug Ag inibidores novos de glutaminil ciclase
RS52163B (sr) * 2004-02-05 2012-08-31 Kyorin Pharmaceutical Co. Ltd. Derivati bicikloestra
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
EP1593671A1 (en) * 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
GEP20094679B (en) 2004-03-15 2009-05-10 Takeda Pharmaceuticals Co Dipeptidyl peptidase inhibitors
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
CN1950349A (zh) 2004-05-04 2007-04-18 默克公司 作为用于治疗或预防糖尿病的二肽基肽酶－ⅳ抑制剂的1,2,4－噁二唑衍生物
US7439370B2 (en) * 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
CN1960990A (zh) * 2004-05-18 2007-05-09 默克公司 作为用于治疗或预防糖尿病的二肽基肽酶－ⅳ抑制剂的环己基丙氨酸衍生物
EP1598341A1 (en) * 2004-05-21 2005-11-23 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
EP1604980A1 (en) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
EP1604989A1 (en) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
CN101087756B (zh) * 2004-07-23 2011-04-06 纽阿达有限责任公司 肽酶抑制剂
EP1623983A1 (en) * 2004-08-05 2006-02-08 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft Heterocyclic compounds useful as DPP-IV inhibitors
DE102004043944A1 (de) * 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20060063719A1 (en) * 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
KR20070073887A (ko) 2004-10-12 2007-07-10 그렌마크 파머수티칼스 에스. 아. 신규한 디펩티딜 펩티다제 ⅳ 억제제, 이를 함유하는약제학적 조성물, 및 이의 제조공정
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
BRPI0516667A (pt) * 2004-11-30 2008-09-16 Hoffmann La Roche compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e utilização desses compostos
US7411093B2 (en) 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
RU2396257C2 (ru) * 2004-12-20 2010-08-10 Ф.Хоффманн-Ля Рош Аг Производные 4-аминопиперидина
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CA2597649A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
WO2006088129A1 (ja) 2005-02-18 2006-08-24 Mitsubishi Pharma Corporation プロリン誘導体の塩、またはその溶媒和物、及びその製造方法
ES2477868T3 (es) 2005-04-22 2014-07-18 Alantos Pharmaceuticals Holding, Inc. Inhibidores de dipeptidil peptidasa-IV
EP1882474B1 (en) * 2005-04-26 2010-11-03 Mitsubishi Tanabe Pharma Corporation Prophylactic/therapeutic agent for abnormalities of lipid metabolism
US7521557B2 (en) * 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
WO2006133160A2 (en) 2005-06-06 2006-12-14 Georgetown University Compositions and methods for lipo modeling
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US20090286722A1 (en) * 2005-09-08 2009-11-19 Utech Limited Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function
EP1943274A2 (en) * 2005-09-08 2008-07-16 Uutech Limited Treatment of diabetes related obesity
ME02005B (me) 2005-09-14 2012-08-31 Takeda Pharmaceuticals Co Inhibitori dipeptidil peptidaze za lečenje dijabetesa
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
EP1971614A1 (en) 2005-11-14 2008-09-24 Probiodrug AG Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors
DE102005054994B4 (de) * 2005-11-18 2015-02-12 Bader Gmbh & Co. Kg Verkleidungsanordnung, insbesondere Maschinenverkleidung, mit einer Schiebetür und Führungsanordnung hierfür
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
WO2007102286A1 (ja) 2006-03-08 2007-09-13 Kyorin Pharmaceutical Co., Ltd. アミノアセチルピロリジンカルボニトリル誘導体の製造方法およびその製造中間体
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US7833730B2 (en) 2006-04-11 2010-11-16 Arena Pharmaceuticals, Inc. Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual
KR20090004950A (ko) 2006-04-12 2009-01-12 프로비오드룩 아게 효소 억제제
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2008017670A1 (en) * 2006-08-08 2008-02-14 Boehringer Ingelheim International Gmbh Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
DK2073810T3 (da) * 2006-09-13 2011-10-31 Takeda Pharmaceutical Anvendelse af 2-6-(3-aminio-piperidin-l-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-ylmethyl-4-fluor-benzonitril til behandling af diabetes, cancer, autoimmune sygdomme og HIV infektion
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
US8143427B2 (en) * 2007-03-22 2012-03-27 Kyorin Pharmaceutical Co., Ltd. Method for producing aminoacetylpyrrolidinecarbonitrile derivative
EP2143443B1 (en) 2007-04-03 2014-11-19 Mitsubishi Tanabe Pharma Corporation A combination of dipeptidyl peptidase iv inhibitor and sweetener for use in the treatment of obesity
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
WO2008141021A1 (en) 2007-05-08 2008-11-20 Concert Pharmaceuticals, Inc. Deuterated derivatives of tetrahydrotriazolopyrazine compounds and their use as dpp-iv inhibitors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CL2008002427A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
NZ600126A (en) * 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
US20090076013A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched sitagliptin
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
EP2915814A3 (en) 2008-07-03 2015-10-07 ratiopharm GmbH Crystalline salts of sitagliptin
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
JP5476305B2 (ja) * 2008-08-07 2014-04-23 杏林製薬株式会社 ビシクロ［２．２．２］オクチルアミン誘導体の製造方法
WO2010018217A2 (en) * 2008-08-15 2010-02-18 Boehringer Ingelheim International Gmbh Organic compounds for wound healing
EP2327406A4 (en) * 2008-08-14 2014-04-09 Kyorin Seiyaku Kk STABILIZED PHARMACEUTICAL COMPOSITION
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
WO2010062863A2 (en) * 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Compositions containing satiogens and methods of use
CN102316872B (zh) 2008-11-26 2016-12-21 萨蒂奥根制药公司 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
WO2010079433A2 (en) 2009-01-07 2010-07-15 Glenmark Pharmaceuticals, S.A. Pharmaceutical composition that includes a dipeptidyl peptidase-iv inhibitor
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
PT2395983T (pt) 2009-02-13 2020-07-03 Boehringer Ingelheim Int Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dp-iv e opcionalmente um agente antidiabético adicional e suas utilizações
EA201101621A1 (ru) 2009-05-15 2012-05-30 Новартис Аг Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
CN102803217B (zh) 2009-05-15 2015-06-17 诺华股份有限公司 作为醛固酮合酶抑制剂的芳基吡啶
EP2435402B1 (en) 2009-05-28 2016-04-13 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
JP5734981B2 (ja) 2009-09-02 2015-06-17 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖ阻害剤としてのアミノテトラヒドロピラン
CN102695546B (zh) 2009-09-11 2014-09-10 前体生物药物股份公司 作为谷氨酰胺酰环化酶抑制剂的杂环衍生物
CA2774015A1 (en) 2009-09-15 2011-03-24 Cerulean Pharma Inc. A cdp-camptothecin conjugate, particle or composition and uses thereof
JP5654608B2 (ja) 2009-11-17 2015-01-14 ノバルティス アーゲー アルドステロンシンターゼ阻害剤としてのアリール−ピリジン誘導体
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
MX2012005987A (es) 2009-11-23 2012-06-25 Cerulean Pharma Inc Polimeros a base de ciclodextrina para administracion terapeutica.
KR20120107080A (ko) 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EP2507234B1 (en) 2009-11-30 2014-03-12 Novartis AG Imidazole derivatives as aldosterone synthase inhibitors
WO2011090940A1 (en) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US8853212B2 (en) 2010-02-22 2014-10-07 Merck Sharp & Dohme Corp Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
WO2011146358A1 (en) 2010-05-21 2011-11-24 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
EP4137137A1 (en) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
KR20220025926A (ko) 2010-06-24 2022-03-03 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2619198A1 (en) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012049566A1 (en) 2010-10-14 2012-04-19 Japan Tobacco Inc. Combination therapy for use in treating diabetes
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9051329B2 (en) 2011-07-05 2015-06-09 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
CN103781788B (zh) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2770990A4 (en) 2011-10-28 2015-03-11 Lumena Pharmaceuticals Inc Gallic acid refluxing agent for the treatment of hypertension and chronic liver disease
PT2771003T (pt) 2011-10-28 2017-07-26 Lumena Pharmaceuticals Llc Inibidores da reciclagem de ácidos biliares para tratamento de doenças hepáticas colestáticas pediátricas
US9115082B2 (en) 2012-01-18 2015-08-25 Catherine Yang Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension
US9073930B2 (en) 2012-02-17 2015-07-07 Merck Sharp & Dohme Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014018350A1 (en) 2012-07-23 2014-01-30 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-iv inhibitors
TWI500613B (zh) 2012-10-17 2015-09-21 Cadila Healthcare Ltd 新穎之雜環化合物
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
EA028583B1 (ru) 2013-02-14 2017-12-29 Новартис Аг Замещенные бис-фенилбутановые производные фосфоновой кислоты в качестве ингибиторов nep (нейтральная эндопептидаза)
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
HK1218252A1 (zh) 2013-07-25 2017-02-10 Novartis Ag 合成apelin多肽之生物结合物
US9902751B2 (en) 2013-12-30 2018-02-27 Mylan Laboratories Limited Process for the preparation of empagliflozin
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
DE102014018663A1 (de) 2014-12-13 2015-03-05 Heinz Kiefer Nachweis von vermehrungsfähigen Zellen zur Überprüfung von Arzneimittel-Wirkstoffangaben bei Zulassungsverfahren
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
CR20170338A (es) 2015-01-23 2017-09-12 Novartis Ag Conjugados de ácidos grasos y apelina sintética con mayor vida media
EP3267994A4 (en) 2015-03-09 2018-10-31 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
WO2017115252A1 (en) 2015-12-28 2017-07-06 Wockhardt Limited An oral osmotic pharmaceutical composition of vildagliptin
KR102411574B1 (ko) * 2016-04-29 2022-06-21 펀다시오 호스피탈 유니버시타리 발 드헤브론-인스티튜트 디 레세르카 망막 신경변성 질환의 국소 안구 치료를 위한 디펩티딜 펩티다제-4 저해제
MX390363B (es) 2016-06-10 2025-03-20 Boehringer Ingelheim Int Combinacion de linagliptina y metformina
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
WO2018162722A1 (en) 2017-03-09 2018-09-13 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Dpp-4 inhibitors for use in treating bone fractures
SG11201909046XA (en) 2017-04-03 2019-10-30 Coherus Biosciences Inc PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
ES2733477T3 (es) 2017-07-04 2019-11-29 Fis Fabbrica Italiana Sintetici Spa Procedimiento eficaz para la preparación de sitagliptina a través de una preparación muy eficaz del intermedio ácido 2,4,5-trifluorofenilacético
MX2020001525A (es) 2017-08-24 2020-03-20 Novo Nordisk As Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
ES2770143T3 (es) 2018-02-13 2020-06-30 Fis Fabbrica Italiana Sintetici Spa Nuevo procedimiento eficiente para la preparación de sitagliptina
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
CA3112958A1 (en) 2018-09-18 2020-03-26 Albert-Ludwigs-Universitat Freiburg Inhibition of histone methyl transferases to treat cancer
EP3887388A1 (en) 2018-11-27 2021-10-06 Novartis AG Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
EP3887363A1 (en) 2018-11-27 2021-10-06 Novartis AG Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
EP4335438A1 (en) 2019-09-17 2024-03-13 Novartis AG Combination therapy with vildagliptin and metformin
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
JP2023536346A (ja) 2020-08-05 2023-08-24 エリプシーズ ファーマ リミテッド シクロデキストリン含有ポリマートポイソメラーゼ阻害剤コンジュゲートおよびｐａｒｐ阻害剤を用いた癌の処置
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
CN120058836B (zh) * 2021-12-24 2025-11-25 西南医科大学 一类具有抗糖尿病活性的化合物及其应用
US20240391941A1 (en) 2023-05-24 2024-11-28 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE296075C (zh)
US2961377A (en) 1957-08-05 1960-11-22 Us Vitamin Pharm Corp Oral anti-diabetic compositions and methods
DE2009743A1 (de) 1970-03-03 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Substituierte Biguanide mit antihyperglykämischer Wirkung
US3960949A (en) 1971-04-02 1976-06-01 Schering Aktiengesellschaft 1,2-Biguanides
CH602612A5 (zh) 1974-10-11 1978-07-31 Hoffmann La Roche
US4935493A (en) 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
US5433955A (en) 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
DD296075A5 (de) * 1989-08-07 1991-11-21 Martin-Luther-Universitaet Halle-Wittenberg,De Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv
ATE164852T1 (de) * 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5462928A (en) * 1990-04-14 1995-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type IV
WO1991017767A1 (en) * 1990-05-21 1991-11-28 New England Medical Center Hospitals, Inc. Method of treating inhibition of dipeptidyl aminopeptidase type iv
FR2674522B1 (fr) * 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
JPH04334357A (ja) 1991-05-02 1992-11-20 Fujirebio Inc 酵素阻害作用を有するアシル誘導体
CA2121369C (en) 1991-10-22 2003-04-29 William W. Bachovchin Inhibitors of dipeptidyl-aminopeptidase type iv
RU2040926C1 (ru) * 1991-11-25 1995-08-09 Анатолий Григорьевич Гриценко Способ лечения сахарного диабета
IL106998A0 (en) 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
FR2696740B1 (fr) 1992-10-13 1994-12-30 Dospharma Sa Dérivés prodrogués de la diméthylbiguanide et applications comme médicaments.
WO1995011689A1 (en) 1993-10-29 1995-05-04 Trustees Of Tufts College Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
EP0658568A1 (en) 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
JPH07228529A (ja) * 1994-02-17 1995-08-29 Zeria Pharmaceut Co Ltd コリンエステラーゼ賦活剤
US5543396A (en) 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5614379A (en) 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
CA2256669A1 (en) 1996-05-29 1997-12-04 Prototek, Inc. Prodrugs of thalidomide and methods for using same as modulators of t-cell function
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
AR016751A1 (es) 1996-11-22 2001-08-01 Athena Neurosciences Inc Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
AU3960400A (en) 1999-03-05 2000-09-28 Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv

Also Published As

Publication number Publication date
EP2289513A2 (de) 2011-03-02
LU91334I2 (fr) 2007-06-18
DE122010000020I1 (de) 2010-07-08
DK0896538T3 (da) 2001-09-24
GR3036788T3 (en) 2002-01-31
LU92612I2 (fr) 2015-10-21
CN1269528C (zh) 2006-08-16
LTPA2014044I1 (lt) 2020-06-10
AU721477B2 (en) 2000-07-06
CA2252576C (en) 2005-04-12
NL300280I1 (nl) 2007-07-02
DK1084705T3 (da) 2014-08-25
CA2252576A1 (en) 1997-11-06
EP1084705A3 (de) 2002-05-15
CN1132578C (zh) 2003-12-31
JP2009137973A (ja) 2009-06-25
AU721477C (en) 2006-12-21
NZ332707A (en) 1999-10-28
LU91382I2 (fr) 2008-02-05
KR20050104428A (ko) 2005-11-02
HK1019204A1 (zh) 2000-01-28
DE122007000083I1 (de) 2008-03-27
NL300280I2 (nl) 2007-09-03
PT1084705E (pt) 2014-09-02
NL300308I1 (nl) 2008-02-01
ATE202705T1 (de) 2001-07-15
DE19616486C5 (de) 2016-06-30
RU2189233C2 (ru) 2002-09-20
EP0896538A1 (de) 1999-02-17
EP1084705A2 (de) 2001-03-21
DE19616486A1 (de) 1997-10-30
US6303661B1 (en) 2001-10-16
LU92613I2 (fr) 2015-10-21
LU92614I2 (fr) 2015-10-21
EP0896538B1 (de) 2001-07-04
CN1216468A (zh) 1999-05-12
EP2289513A3 (de) 2013-07-10
DE19616486C2 (de) 1999-08-12
LU92615I2 (fr) 2015-10-21
DE122007000038I1 (de) 2007-08-16
KR100950722B1 (ko) 2010-03-31
JP2012092136A (ja) 2012-05-17
JP2001510442A (ja) 2001-07-31
PT896538E (pt) 2001-11-30
LU92611I2 (fr) 2015-10-21
WO1997040832A1 (de) 1997-11-06
SI1084705T1 (sl) 2014-10-30
KR20000064559A (ko) 2000-11-06
LTPA2014043I1 (lt) 2020-06-10
KR20100036363A (ko) 2010-04-07
KR20120014064A (ko) 2012-02-15
NL300308I2 (nl) 2008-04-01
FR14C0089I1 (fr) 2015-01-23
ES2505665T3 (es) 2014-10-10
LTPA2014045I1 (lt) 2020-06-10
KR100617676B1 (ko) 2006-11-30
KR20070086832A (ko) 2007-08-27
AU3023397A (en) 1997-11-19
HK1033420A1 (zh) 2001-08-31
LTC1084705I2 (lt) 2017-05-10
EP1084705B1 (de) 2014-06-25
ES2158562T3 (es) 2001-09-01
DE59703959D1 (de) 2001-08-09

Similar Documents

Publication Publication Date Title
CN1132578C (zh) 降低哺乳动物血糖水平的二肽基肽酶iv效应物的用途
US20170007582A1 (en) Use of Dipeptidyl Peptidase IV Effectors for Normalizing the Blood Glucose Level in Mammals
EP0995440B1 (de) Verfahren zur Stiegerung des Blutglukosespiegels in Säugern
Kim et al. KR-62436, 6-{2-[2-(5-cyano-4, 5-dihydropyrazol-1-yl)-2-oxoethylamino] ethylamino} nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity
Ahrén et al. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism
US20130137629A1 (en) Combination treatment for metabolic disorders
WO2005123132A2 (en) Use of liver-selective glucokinase activators
Salvatore et al. Progress in the oral treatment of type 2 diabetes: update on DPP-IV inhibitors
HK1019204B (zh) 降低哺乳动物血糖水平的二肽基肽酶iv效应物的用途
KR20060119927A (ko) 혈당 조절을 위한 조합 요법
FREED et al. Pospisilik et al.(43) Pub. Date: Jan. 17, 2002
HK1033420B (zh) 降低哺乳動物血糖水平的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: PULOSIDIEA CO., LTD.

Free format text: FORMER OWNER: BIOLOGICAL MEDICINE AG

Effective date: 20050318

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20050318

Address after: oxford

Applicant after: Prosidion Ltd.

Address before: Halle, Federal Republic of Germany

Applicant before: Biological Medicine AG

C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20060816